Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients

Billing H, Giese T, Sommerer C, Zeier M, Feneberg R, Meuer S, Tönshoff B. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplantation 2010: 14:844-851. © 2010 John...

Full description

Saved in:
Bibliographic Details
Main Authors: Billing, Heiko (Author) , Giese, Thomas (Author) , Sommerer, Claudia (Author) , Zeier, Martin (Author) , Feneberg, Reinhard (Author) , Meuer, Stefan (Author) , Tönshoff, Burkhard (Author)
Format: Article (Journal)
Language:English
Published: 28 April 2010
In: Pediatric transplantation
Year: 2010, Volume: 14, Issue: 7, Pages: 844-851
ISSN:1399-3046
DOI:10.1111/j.1399-3046.2010.01354.x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1399-3046.2010.01354.x
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1399-3046.2010.01354.x
Get full text
Author Notes:Heiko Billing, Thomas Giese, Claudia Sommerer, Martin Zeier, Reinhard Feneberg, Stefan Meuer, and Burkhard Tönshoff
Description
Summary:Billing H, Giese T, Sommerer C, Zeier M, Feneberg R, Meuer S, Tönshoff B. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplantation 2010: 14:844-851. © 2010 John Wiley & Sons A/S. Abstract: Pharmacokinetic monitoring of CsA is unsatisfactory, because at comparable CsA blood concentrations, the frequency and severity of adverse effects vary considerably among patients. We have therefore recently developed a precise, reliable, and robust whole-blood pharmacodynamic assay that measures the suppression of CsA-target genes in T lymphocytes. Because of the different characteristics of CsA pharmacokinetics in children and the higher propensity for infectious complications, this assay requires validation in the pediatric patient population. We therefore quantified in a prospective study of 45 pediatric renal transplant recipients the residual expression of NFAT-regulated genes in lymphocytes by RT-PCR and correlated these findings with the frequency of recurrent infections in the maintenance period post-transplant. Patients with recurrent infections showed a significantly stronger inhibition of NFAT-regulated gene expression (18.2%) than patients without recurrent infections (31.7%; p = 0.012). This difference was specific, because various PK parameters of CsA and the concomitant immunosuppressive therapy were comparable between patients. Multivariate regression analysis showed that patient age and residual NFAT-regulated gene expression were the only independent determinants of recurrent infections. By ROC curve analysis, a cutoff value of 23% residual NFAT-regulated gene expression had the highest sensitivity (71.1%) and specificity (65.4%) for the discrimination of patients with and without recurrent infections. Pharmacodynamic monitoring of CsA by measurement of residual NFAT-regulated gene expression in T lymphocytes has the potential to identify over-immunosuppressed pediatric renal transplant recipients and is therefore a useful tool for the optimization of CsA therapy.
Item Description:Gesehen am 02.02.2023
Physical Description:Online Resource
ISSN:1399-3046
DOI:10.1111/j.1399-3046.2010.01354.x